Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma

Sarcoma

Volumn 2010, Issue , 2010, Pages

  Minchom, Anna ^a   Jones, Robin L ^b   Fisher, Cyril ^a   Al Muderis, Omar ^a   Ashley, Sue ^a   Scurr, Michelle ^a   Karavasilis, Vasilios ^a   Judson, Ian R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TRABECTEDIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; SYNOVIUM; TREATMENT OUTCOME;

EID: 77953529849     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2010/264360     Document Type: Article

References (16)

1. Singer S., Demetri G. D., Baldini E. H., Fletcher C. D. M., Management of soft-tissue sarcomas: an overview and update The Lancet Oncology 2000 1 2 75 85
2. Clark M. A., Fisher C., Judson I., Thomas J. M., Soft-tissue sarcomas in adults New England Journal of Medicine 2005 353 7 701 711
3. Blay J.-Y., van Glabbeke M., Verweij J., Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy European Journal of Cancer 2003 39 1 64 69
4. Sleijfer S., Seynaeve C., Verweij J., Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care Oncologist 2005 10 10 833 841
5. Hartmann J. T., Patel S., Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma Drugs 2005 65 2 167 178 (Pubitemid 40139381)
6. Fury M. G., Antonescu C. R., Van Zee K. J., Brennan M. F., Maki R. G., A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy Cancer Journal 2005 11 3 241 247
7. Aranha O., Agulnik M., Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions Expert Opinion on Therapeutic Targets 2008 12 2 197 207
8. Sleijfer S., Ray-Coquard I., Papai Z., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043) Journal of Clinical Oncology 2009 27 19 3126 3132
9. Ludwig J. A., Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection Current Oncology Reports 2008 10 4 329 337
10. Verma S., Younus J., Stys-Norman D., Haynes A. E., Blackstein M., Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma Cancer Treatment Reviews 2008 34 4 339 347
11. Van Glabbeke M., Van Oosterom A. T., Oosterhuis J. W., Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimensa European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Journal of Clinical Oncology 1999 17 1 150 157
12. Van Glabbeke M., Verweij J., Judson I., Nielsen O. S., Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas European Journal of Cancer 2002 38 4 543 549
13. Karavasilis V., Seddon B. M., Ashley S., Al-Muderis O., Fisher C., Judson I., Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer 2008 112 7 1585 1591
14. Lara P. N. Jr., Redman M. W., Kelly K., Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials Journal of Clinical Oncology 2008 26 3 463 467
15. Lorigan P., Verweij J., Papai Z., Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Journal of Clinical Oncology 2007 25 21 3144 3150 (Pubitemid 47218064)
16. Jones R. L., Fisher C., Al-Muderis O., Judson I. R., Differential sensitivity of liposarcoma subtypes to chemotherapy European Journal of Cancer 2005 41 18 2853 2860